Dr. Patel on Induction in Patients With Mantle Cell Lymphoma

Video

Krish Patel, MD, medical oncologist, Swedish Cancer Institute, discusses induction therapy in patients with mantle cell lymphoma (MCL).

Krish Patel, MD, medical oncologist, Swedish Cancer Institute, discusses induction therapy in patients with mantle cell lymphoma (MCL).

Data compiled from a combination of 2 phase II clinical trials that were conducted at the Dana-Farber Cancer Institute and Washington University in St. Louis, as well as some patients who were treated off clinical trial, examined the use of bendamustine and rituximab (Rituxan; BR) as induction therapy in MCL. Investigators examined overall responses, progression-free survival, and overall survival using the induction regimen for 3 treatment cycles. If patients had an appropriate clinical response, they went on to receive 3 cycles of rituximab and cytarabine before undergoing an autologous stem cell transplant.

This study was presented at the 2018 ASH Annual Meeting and shows compelling evidence for the use of BR as induction therapy in patients with MCL, says Patel. However, the regimen needs to be studied further in additional randomized prospective studies to confirm the benefit observed in this analysis.

Recent Videos
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology
Jamie Jacobs, PhD, the program director of the center for psychiatric oncology & behavioral sciences at Mass General Cancer Center
Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology
Sarah Hein, PhD, the chief executive officer and cofounder of March Biosciences
Brian Kim, MBA, the chief executive officer of Mission Bio
Related Content
© 2025 MJH Life Sciences

All rights reserved.